LLY
$989.12
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Intraday
Recent News
Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs top healthcare stocks. On March 10, analysts at Bernstein SocGen reiterated an Outperform rating on Eli Lilly (NYSE:LLY) with a $1,300 price target. The positive stance comes on the heels of the company launching the Employer Connect platform to enhance access to its obesity medications […]
Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill?
Structure Therapeutics shares surged Monday after the biotech said its daily pill helped patients lose up to 39 pounds over a 44-week study.
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price?
Eli Lilly's stock is down this year, and its high valuation may be a big reason why.
Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story
Eli Lilly (NYSE:LLY) reported positive topline Phase 3 results for EBGLYSS (lebrikizumab) in pediatric patients with moderate to severe atopic dermatitis. The data support a potential label expansion into pediatric use, further building out Lilly's immunology and dermatology presence. This update extends the EBGLYSS story beyond adult indications and arrives as the company continues to invest in its broader pipeline. Eli Lilly, trading at around $985.08, has already delivered very large...
A New GLP-1 Pill Melted Away the Pounds. Is Structure Therapeutics a Takeover Candidate?
Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.